<DOC>
	<DOCNO>NCT02175485</DOCNO>
	<brief_summary>Primary Objective : To collect analyze clinical data Allergic Rhinitis patient ' Total Nasal Symptom Score ( TNSS ) change Dellegra internal use high density pure Japanese cedar pollen exposure . Secondary Objective : To collect analyze clinical data Allergic Rhinitis patient ' change Total Symptom Score ( TSS ) amount nasal discharge , safety , overall patient ' impression efficacy Dellegra Dellegra internal use high density pure Japanese cedar pollen exposure .</brief_summary>
	<brief_title>Evaluation Efficacy Dellegra Exposure Unit</brief_title>
	<detailed_description>It 8 day minimum 17 day depend screen visit post-treatment observation allowance .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Inclusion criterion : Patients seasonal allergic rhinitis . Patients history symptom Japanese cedar pollinosis least 2 year . Positive radioallergosorbent test ( RAST ) Japanese cedar pollen antigen ( CAPRAST class &gt; =2 ) within 1.5 year exposure test . Patients Total Nasal Symptom Score 8 , nasal congestion score 2 ( moderate ) least 1 assessment point 90 150 minute start screen exposure . Age ≥20 ≤65 year . Patients write informed consent . Exclusion criterion : Patients symptoms perennial allergic rhinitis . Patients severe asthma , bronchiectasis , severe hepatic , renal , cardiac dysfunction , hematological , endocrine disease , serious complication . Patients nasal disease ( hypertrophic rhinitis , paranasal sinusitis , nasal polyp , deviation nasal septum , etc . ) eye disease could interfere judgment efficacy Dellegra Combination Tablets . Patients evidence upper and/or lower respiratory tract inflammation ( acute rhinitis , chronic rhinitis , congestive rhinitis , atrophic rhinitis , purulent nasal discharge , sinusitis presence coldlike , etc . ) day treatment exposure . Patients take follow medication may affect evaluation Dellegra Combination Tablets ( except use topical preparation investigator/subinvestigator judge affect efficacy evaluation ; treat site different , etc . ) : Within 2 week prior day screen exposure test : Antiallergic drug , antihistamine ( H1 H2 blocker : oral administration , nose drop , eye drop , injection , topical use ) , anticholinergic agent , vasoconstrictor nose drop , antihistaminecontaining cold remedy , agent expect antiallergic/antihistaminic effect ( include Chinese medicine glycyrrhizin ) , agent indicate allergic symptom ( sneeze , rhinorrhea , nasal congestion , eye itch etc. ) . Steroids ( oral , inhaled , nose drop , eye drop , topical use ) , immunosuppressant ( oral , topical use , inject ) , azole fungicide , histamine contain gammaglobulin preparation . Within 4 week prior day screen exposure test : Depot steroid preparation . Patients consider investigator/subinvestigator unsuitable enrollment study criterion . Patients history hypersensitivity antihistamines antihistaminic agent ( fexofenadine HCI include ) , pseudoephedrine hydrochloride . Patients severe hypertension severe coronary artery disease , narrow angle glaucoma , urinary retention , show sensitivity adrenergic agent ( manifestation include insomnia , dizziness , weakness , tremor , arrhythmia ) . Women pregnant , may pregnant , currently breastfeed . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>